These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 10357386

  • 1. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
    Revicki DA, Moyle G, Stellbrink HJ, Barker C.
    AIDS; 1999 May 07; 13(7):851-8. PubMed ID: 10357386
    [Abstract] [Full Text] [Related]

  • 2. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA, Swartz C, Wu AW, Haubrich R, Collier AC.
    Antivir Ther; 1999 May 07; 4(1):35-44. PubMed ID: 10682127
    [Abstract] [Full Text] [Related]

  • 3. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L.
    N Engl J Med; 1996 Apr 18; 334(16):1011-7. PubMed ID: 8598838
    [Abstract] [Full Text] [Related]

  • 4. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.
    Race E, Gilbert SM, Sheldon JG, Rose JS, Moffatt AR, Sitbon G, Dissanayeke SR, Cammack N, Duncan IB.
    AIDS; 1998 Aug 20; 12(12):1465-74. PubMed ID: 9727567
    [Abstract] [Full Text] [Related]

  • 5. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM, ACTG 303 Study Team.
    AIDS Res Hum Retroviruses; 2000 Sep 20; 16(14):1337-44. PubMed ID: 11018853
    [Abstract] [Full Text] [Related]

  • 6. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.
    West Afr J Med; 2002 Sep 20; 21(2):83-6. PubMed ID: 12403023
    [Abstract] [Full Text] [Related]

  • 7. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
    Delta Coordinating Committee.
    HIV Med; 2001 Jul 20; 2(3):181-8. PubMed ID: 11737399
    [Abstract] [Full Text] [Related]

  • 8. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 20; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 9. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
    Cohen Stuart JW, Schuurman R, Burger DM, Koopmans PP, Sprenger HG, Juttmann JR, Richter C, Meenhorst PL, Hoetelmans RM, Kroon FP, Bravenboer B, Hamann D, Boucher CA, Borleffs JC.
    AIDS; 1999 May 07; 13(7):F53-8. PubMed ID: 10357371
    [Abstract] [Full Text] [Related]

  • 10. Impact of zidovudine plus lamivudine or zalcitabine on health-related quality of life.
    Scott-Lennox JA, Mills RJ, Burt MS.
    Ann Pharmacother; 1998 May 07; 32(5):525-30. PubMed ID: 9606471
    [Abstract] [Full Text] [Related]

  • 11. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ, Bouza E, Antunes F, Smith D, Harris R, Warburg M, Walker M.
    Antivir Ther; 1997 Dec 07; 2(4):229-36. PubMed ID: 11327442
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
    Delta Coordinating CommitteeMedical Research Council Clinical Trials Unit, University College London Medical School, UK., Delta Virology Committee.
    AIDS; 1999 Jan 14; 13(1):57-65. PubMed ID: 10207545
    [Abstract] [Full Text] [Related]

  • 14. MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.
    Katlama C, Pellegrin JL, Lacoste D, Aquilina C, Raffi F, Pialoux G, Vittecoq D, Raguin G, Lantz O, Mouroux M, Calvez V, Trylesinski A, Montestruc F, Dohin E, Goehrs JM, Delfraissy JF.
    HIV Med; 2001 Jan 14; 2(1):20-6. PubMed ID: 11737372
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
    Sangkitporn S, Shide L, Klinbuayaem V, Leenasirimakul P, Wirayutwatthana NA, Leechanachai P, Dettrairat S, Kunachiwa W, Thamlikitkul V.
    Southeast Asian J Trop Med Public Health; 2005 May 14; 36(3):704-8. PubMed ID: 16124442
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
    AIDS; 1999 Apr 01; 13(5):565-73. PubMed ID: 10203381
    [Abstract] [Full Text] [Related]

  • 19. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM, Winters MA, Lawrence J, Merigan TC.
    AIDS; 1999 Feb 25; 13(3):359-65. PubMed ID: 10199226
    [Abstract] [Full Text] [Related]

  • 20. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
    Henry K, Erice A, Tierney C, Balfour HH, Fischl MA, Kmack A, Liou SH, Kenton A, Hirsch MS, Phair J, Martinez A, Kahn JO.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec 01; 19(4):339-49. PubMed ID: 9833742
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.